Published in Cell Death Differ on March 04, 2016
The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death. EMBO J (2017) 0.81
In Vitro and In Vivo Evaluation of (89)Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy. Theranostics (2016) 0.79
Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer. Cell Mol Life Sci (2016) 0.78
Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction. Oncoimmunology (2016) 0.78
Differences and Similarities in TRAIL- and Tumor Necrosis Factor-Mediated Necroptotic Signaling in Cancer Cells. Mol Cell Biol (2016) 0.75
Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. Oncotarget (2016) 0.75
Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy. Cell Death Differ (2016) 0.75
The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation. Oncotarget (2016) 0.75
JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells. Oncogenesis (2017) 0.75
Executioner caspases and CAD are essential for mutagenesis induced by TRAIL or vincristine. Cell Death Dis (2017) 0.75
Identification of miRNA-7 by genome-wide analysis as a critical sensitizer for TRAIL-induced apoptosis in glioblastoma cells. Nucleic Acids Res (2017) 0.75
Secretory stressors induce intracellular death receptor accumulation to control apoptosis. Cell Death Dis (2017) 0.75
Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells. Oncotarget (2017) 0.75
Multiwell capillarity-based microfluidic device for the study of 3D tumour tissue-2D endothelium interactions and drug screening in co-culture models. Sci Rep (2017) 0.75
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer (2017) 0.75
Endothelial cell apoptosis in angiogenesis and vessel regression. Cell Mol Life Sci (2017) 0.75
Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell (1998) 16.08
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell (1998) 13.87
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med (1999) 9.78
Inhibition of death receptor signals by cellular FLIP. Nature (1997) 9.58
tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev (2000) 8.35
Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (1998) 8.11
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol (2004) 6.76
Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov (2003) 6.66
The receptor for the cytotoxic ligand TRAIL. Science (1997) 6.39
Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature (2011) 6.31
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22
Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell (2009) 5.55
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev (2010) 5.26
cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell (2011) 4.78
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med (2000) 4.40
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J (1997) 4.28
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med (2007) 3.99
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem (1998) 3.88
Caspase activation: the induced-proximity model. Proc Natl Acad Sci U S A (1999) 3.86
Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med (1998) 3.72
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 3.45
Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity (1997) 3.33
Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev (2010) 3.30
Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther (2005) 3.27
The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov (2008) 3.25
The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity (1997) 3.11
XIAP discriminates between type I and type II FAS-induced apoptosis. Nature (2009) 3.00
Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem (2001) 2.94
c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J (2002) 2.91
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med (2001) 2.87
TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol (2000) 2.80
The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem (2002) 2.75
Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem (2010) 2.72
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm (2008) 2.71
Inhibition of fas death signals by FLIPs. Curr Opin Immunol (1998) 2.67
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med (2001) 2.66
Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature (2009) 2.54
Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol (2003) 2.50
TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol (2007) 2.49
Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med (1997) 2.46
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell (1999) 2.42
A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol (1997) 2.31
Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem (1997) 2.26
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther (2001) 2.13
The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature (2008) 2.11
Activation of caspases-8 and -10 by FLIP(L). Biochem J (2004) 2.11
Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol (2004) 1.99
TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev (2008) 1.94
Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol (1992) 1.94
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res (2007) 1.91
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ (2005) 1.90
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem (2004) 1.88
Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem (2005) 1.87
Getting TRAIL back on track for cancer therapy. Cell Death Differ (2014) 1.86
Initiator caspases in apoptosis signaling pathways. Apoptosis (2002) 1.86
Characterization of two receptors for TRAIL. FEBS Lett (1997) 1.82
The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol (2000) 1.80
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene (2012) 1.75
The promise of TRAIL--potential and risks of a novel anticancer therapy. J Mol Med (Berl) (2007) 1.73
XIAP, the guardian angel. Nat Rev Mol Cell Biol (2001) 1.72
Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol (1999) 1.71
Apoptosis-inducing factor: vital and lethal. Trends Cell Biol (2006) 1.70
Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci U S A (2005) 1.69
Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem (2000) 1.68
TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol (1997) 1.68
Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer (2015) 1.66
A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol Cell (2012) 1.64
FLIP(L) induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity. Biochem J (2011) 1.64
Is TRAIL the holy grail of cancer therapy? Apoptosis (2009) 1.62
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ (2004) 1.62
The structure of FADD and its mode of interaction with procaspase-8. Mol Cell (2006) 1.61
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ (2008) 1.61
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ (2013) 1.60
Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol (1999) 1.57
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol (2011) 1.55
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene (2006) 1.55
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res (2006) 1.53
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol (2006) 1.52
Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci (2003) 1.52
FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J Biol Chem (2000) 1.51
XIAP inhibition of caspase-3 preserves its association with the Apaf-1 apoptosome and prevents CD95- and Bax-induced apoptosis. Cell Death Differ (2002) 1.47
Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci U S A (2006) 1.45
Cell death induction by receptors of the TNF family: towards a molecular understanding. FEBS Lett (1997) 1.44
Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem (2001) 1.42
Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res (1997) 1.42
MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem (2001) 1.41
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem (2005) 1.41
Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer (1997) 1.40
TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat (2008) 1.39
TRAIL and cancer therapy. Cancer Lett (2008) 1.38
TRAILing death in cancer. Mol Aspects Med (2009) 1.36
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther (2007) 1.34
A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry (2000) 1.34
Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol Eng (2001) 1.32